# OnCo record pyrotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pyrotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pyrotinib" ;
  schema:name "Pyrotinib"@en ;
  schema:description "Pyrotinib is an irreversible pan-ErbB kinase inhibitor pill (EGFR, HER2, HER4) from Jiangsu Hengrui, approved in China since 2018 but not in the US or EU. It is the standard HER2 pill there, given with capecitabine after trastuzumab, and the comparator that new Chinese HER2 ADCs are beating; diarrhoea affects nearly every patient."@en ;
  schema:url <https://onco.cc/drugs/pyrotinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pyrotinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule irreversible pan-HER kinase inhibitor" ;
  schema:alternateName "Airuini" ;
  onco:approval "China 2018: HER2+ advanced breast cancer with capecitabine" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:trials <https://onco.cc/trials/horizon-breast01/>, <https://onco.cc/trials/nct06015048/>, <https://onco.cc/trials/nct05482568/>, <https://onco.cc/trials/nct03980054/> .